New monitor aims to stop dangerous ketosis for diabetics on Kidney-Protecting drug
NCT ID NCT07325201
Summary
This study aims to create a safety system so people with type 1 diabetes and mild-to-moderate kidney disease can use a medication called sotagliflozin, which protects the heart and kidneys, without raising their risk of diabetic ketoacidosis (DKA). Researchers will have 80 participants wear a combined glucose and ketone monitor to track their levels and identify risk factors. The goal is to develop better reports from this device to help patients and doctors prevent dangerous ketone buildups before they become an emergency.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
International Diabetes Center
Minneapolis, Minnesota, 55416, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.